Market Place
Sourcing Support
Renalys Pharma To Be Acquired By Chugai Pharmaceutical
24 Oct 2025 //
PR NEWSWIRE
Renalys Pharma Backs Alport Syndrome Registry Study
22 Oct 2025 //
PR NEWSWIRE
Renalys Pharma Secure Japan PMDA Deal For Sparsentan Ph3 for FSGS
17 Oct 2025 //
PR NEWSWIRE
Renalys Completes Phase III Trial Data Collection For Sparsentan
10 Oct 2025 //
PR NEWSWIRE
Renalys Completes Phase 3 Enrollment For Sparsentan In Japan
30 Jan 2025 //
PR NEWSWIRE
Sparsentan Receives Orphan Drug Designation for IgA Nephropathy
03 Dec 2024 //
PR NEWSWIRE
Renalys Pharma Doses First Patient In Phase III IgA Nephropathy Trial
18 Jul 2024 //
PR NEWSWIRE
Renalys Pharma Raises ¥6.0Bn Series A For Asian Kidney Treatments
17 Jul 2024 //
PR NEWSWIRE
Renalys Submits an IND App for a Ph III Trial of sparsentan for IgA Nephropathy
07 Apr 2024 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.